Test Directory

Physician Portal
Patient Portal

Total PSA

Alternate Name: Total_PSA

  | Prostate Specific Antigen (tPSA)

SAL Code:

716

CPT:

84153

Loinc:

2857-1

Turn Around Time:

1 Day

Setup:

Daily

Units:

ng/mL

Department:

Tumor Markers

Performing Laboratory:

Sherman Abrams Laboratory

Methodology:

Electrochemiluminescence immunoassay (ECLIA)

Specimen Requirements:

Primary Tube:

SST

Primary Substance:

Serum

Alternate Sample Info:

EDTA Lavender Top Tube

Temperature

Period

Stable Ambient:

1 Day

Stable Fridge:

5 Days

Stable Frozen:

6 Months

Rejection Criteria:

Improper labeling

Clinical Info:

This immunoassay, a quantitative in vitro diagnostic test for total (free + complexed) prostate-specific antigen (tPSA) in human serum and plasma, is indicated for the measurement of total PSA in conjunction with digital rectal examination (DRE) as an aid in the detection of prostate cancer in men aged 50 years or older. Prostate biopsy is required for diagnosis of prostate cancer. The test is further indicated for serial measurement of tPSA to aid in the management of cancer patients.
PLEASE NOTE:
The measured tPSA value of a patient's sample can vary depending on the testing procedure used. tPSA values determined on patient samples by different testing procedures should not be directly compared with one another and could be the cause of erroneous medical interpretations. If there is a change in the tPSA assay procedure used while monitoring therapy, then the tPSA values obtained upon changing over to the new procedure must be confirmed and interpreted with caution.

Additional Information:

Elevated concentrations of PSA in serum are generally indicative of a pathologic condition of the prostate.
As PSA is also present in para-urethral and anal glands, as well as in breast tissue or with breast cancer, low levels of PSA can also be detected in sera from women. PSA may still be detectable even after radical prostatectomy.
The main areas in which PSA determinations are employed are the monitoring of progress and efficiency of therapy in patients with prostate carcinoma or receiving hormonal therapy.
The steepness of the rate of fall in PSA down to no-longer detectable levels following radiotherapy, hormonal therapy or radical surgical removal of the prostate provides information on the success of therapy.
An inflammation or trauma of the prostate (e.g. in cases of urinary retention or following rectal examination, cystoscopy, colonoscopy, transurethral biopsy, laser treatment or ergometry) can lead to PSA elevations of varying duration and magnitude.

Sample Collection:

Collect patient samples using standard phlebotomy techniques. Click here for additional collection instructions.

Test Information:

Components:

Brooklyn Navy Yard
Building 292, Suite 416
63 Flushing Avenue
Brooklyn, NY 11205

Twitter Linkedin Facebook